VKTX

Viking Therapeutics Inc

NASDAQ: VKTX · HEALTHCARE · BIOTECHNOLOGY

$33.11

-0.96% today

Updated 2026-07-30

Market cap

$4.22B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.15

Dividend yield

—

52W range

$23 – $43

Volume

2.4M

Market cap

$4.22B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.15

Dividend yield

—

52W range

$23 – $43

Volume

2.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.3

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

2.8

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$92.58

+179.61%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

5 Strong Buy13 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-113.98M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-68.87M	$-85.89M	$-109.96M	$-359.64M	$-158.32M
EPS	—	—	—	—	$-4.15
Free cash flow	$-48.40M	$-73.38M	$-87.79M	$-278.69M	$-113.98M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
VKTX	$4.22B	23	4.3	3.0	5.0	6.3	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Viking Therapeutics Inc trades at $33.11. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 2.76, it sits in the grey zone.

Frequently asked questions

What is Viking Therapeutics Inc's stock price?

Viking Therapeutics Inc (VKTX) trades at $33.11.

Is Viking Therapeutics Inc overvalued?

Viking Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Viking Therapeutics Inc (VKTX)?

The 12-month analyst consensus target is $92.58, about 179.6% above the current $33.11. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Viking Therapeutics Inc's Altman Z-Score is 2.76, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-70.00%

Beta0.66

50D MA$33.22

200D MA$33.60

Shares out0.12B

Float0.11B

Short ratio—

Avg volume2.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

VKTX vs LLY →VKTX vs JNJ →VKTX vs ABBV →Stock screener →